Thursday, March 31, 2022

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia

 Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the award of the 24th patent, Lexaria already had a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.”

To view the full article, visit https://ibn.fm/foM47

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: